阿戈梅拉丁在治疗双极性抑郁症方面具有有前途的潜力-系统性审查
Junyao Li1, Huirong Luo1, Qinghua Luo1
1Department of Psychiatry, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
International journal of psychiatry in clinical practice
|December 19, 2024
概括
阿戈梅拉丁 (AGO) 对双极性抑郁症治疗具有前景,在系统性审查中证明了有效性和良好的耐受性. 需要进一步的大规模试验来证实这些发现用于双极性抑郁症管理.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 在双相抑郁症中使用抗抑郁药是有争议的.
- 阿戈梅拉丁 (AGO) 对主要抑郁障碍 (MDD) 有效,但对双极性抑郁症研究不足.
研究的目的:
- 系统地审查关于阿戈梅拉丁 (AGO) 治疗双极性抑郁症的疗效和安全性的临床证据.
主要方法:
- 对双相情感患者的阿戈梅拉丁 (AGO) 试验的系统审查.
- 在PubMed,MEDLINE,Embase和Cochrane数据库中进行了搜索.
- 综合了关于疗效 (情绪,节奏) 和耐受性的证据.
主要成果:
- 包括6项研究,共272名参与者;44%是女性.
- 阿戈梅拉丁 (AGO) (每天25-50毫克),可与情绪稳定剂 (MS) 一起使用或不使用.
- 观察到抑郁症得分和反应率的改善 (43%-91%在6-12周内);注意到迅速发作.
- 阿戈梅拉丁 (AGO) 表现出良好的耐受性,没有显著的情绪转换风险.
结论:
- 阿戈梅拉丁 (AGO) 是对双极性抑郁症的一种有前途的治疗方法,具有显著的疗效和耐受性.
- 需要使用同质组进行更大,更严格的设计试验,以进一步验证阿戈梅拉丁 (AGO) 的作用.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Mania and Antimanic Drugs: Overview
130
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
130
Depression: Overview
215
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
215
Sedatives and Hypnotics Drugs: Miscellaneous Agents
145
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
145
Management of Insomnia
230
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
230
Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25


